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ABSTRACT
The biological etiology of mental health disorders: Social influences and change potential
of practitioners’ beliefs
Donna M. Midkiff
This study was designed to examine mental health professionals’ strength of belief in
biological causation of several syndromes including ADHD, unipolar depression, anxiety
disorders, and schizophrenia and whether a three-hour educational program will alter their
thinking. Findings suggest that pre-training, mental health professionals’ reported strength of
belief regarding the etiology of many mental health disorders tends toward the biologically
based. Also, this study demonstrated that attendance at a three hour training program is able to
reduce the expressed acceptance of biological causation of such disorders. The social influences
of pharmaceutical direct to consumer advertising and medical guild dominance, as well as
empiricism, contributed significantly to prediction of strength of belief in biological causation.
Of the three variables, empirical data had the greatest influence. These findings suggest that as
mental health professionals’ are exposed to social influences that may be contributing to belief
systems supporting biological causation, it is critical examination of empirical data said to
support biological causation that contributes the most robust change in expressed belief.
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Chapter 1
Introduction

Worldview
When considering the causes of behavior, especially abnormal behavior, including
behaviors that define diagnostic syndromes, the discussion usually takes one of three directions –
biology, environment (learning), or some combination of the two. Individuals in the mental
health and behavioral health fields frequently become devoted to one of these three worldviews.
Data show an ebb and flow of the strength of each worldview within the professional community
over the years (Durand & Barlow, 2003; Davidson & Neal, 1994). The biological causation
model has gained substantial influence over the past 30 years, but the validity of empirical
support for it remains a topic of ongoing debate (Wyatt, 2003).
The extent to which professionals in the mental health field come to subscribe to one of
these worldviews is of interest, as are the variables that influence those processes. That is
because once a worldview of abnormal behavior is in place, one tends to interpret instances of
behavior (hallucination, delusions, irrational fears, feelings of depression, and “normal” behavior
etc) in light of that worldview. Those interpretations then influence the practitioner’s efforts at
prevention and treatment, as well as the consumer’s acceptance of specific forms of prevention
or treatment (Langer & Ableson, 1974). Yet, at times the data supporting a particular view of
causation and treatment of a given behavioral disorder are not as powerful or convincing as one
might suppose (Seligman, 1998).
The strength and influence of a worldview is evident in the story of Wilhelm Reich.
Reich was a physician-scientist, born in 1897 in the Austrian province of Galicia.

Reich
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graduated from the Medical School of the University of Vienna in 1922. He was a student of
Sigmund Freud, and a psychoanalyst before his clinical studies led him into the laboratory and
into investigations of the energy processes in nature. Reich ultimately came to the United States
where he went on to claim that he had discovered a universal cosmic and biological energy
present everywhere and detectable through specified experiments. He called this energy orgone.
He built a box-like apparatus with organic material on the outside and metal on the inside that he
called an “orgone accumulator”, which he believed collected and accumulated orgone energy
that existed in the atmosphere. He claimed that exposure to orgone, particularly through sitting in
the accumulator, promoted health and vitality, and was an effective treatment for cancer. He also
claimed to detect another energy, oranur or deadly orgone radiation (DOR), which produced
negative health effects and reacted to orgone. He also built a device he called a “cloud buster”,
with which he claimed he could manipulate the weather by manipulating the orgone in the
atmosphere. Thousands of people came to accept his worldview as evidenced by their purchases
of the “accumulator” and other of his devices, yet they failed to be helped. Reich was taken to
court for shipment of fraudulent devices by the Food and Drug Administration (FDA). The court
ordered his books and research burned and his equipment destroyed. Reich was given a prison
sentence, and he died in federal prison in 1957 (Swalley, 1997).
A more recent example in which a theoretical model of causation influenced clinical
practice with negative effects was frontal lobotomies (Stuss & Alexandar, 2005). The frontal
lobe is thought to be the control center in the brain, specifically affecting the planning, initiation
and regulation of goal-directed behavior (Mahurin, Velligan, & Miller, 1998). In the mid 1930’s
scientists began experimenting with frontal lobe cutting in chimpanzees. In these experiments
aggressive animals became much calmer. The docile chimps looked to be much better off than
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prior to the experiment.

These experiments transitioned into accepted medical treatment

interventions for the mentally unstable (Stuss, et al., 2005). However, psychiatric patients who
underwent frontal lobotomies experienced significant neurological deficits as a result. Patients
were noted to exhibit little spontaneous facial expression, they had difficulty interpreting
environmental cues, and experienced problems with speaking, also known as Broca’s Aphasia
(Kolb & Miller, 1981; Brown, 1972). These patients had trouble responding to questions, and
their associative learning skills were impaired (Kucharski, 1984).

This treatment was an

accepted alternative in many hospitals. Patients on whom the operation was performed had a
variety of diagnoses, including schizophrenia, obsessive-compulsive disorder, and affective
illnesses. People did not begin to realize the ramifications of the operation until it became clear,
through observation, that lobotomized individuals were far from normal or happy, and that in
actuality, the appearance of a less crazed nature had simply been mistaken for (what was in some
cases) a total loss of the individual’s personality (Burgler, 2005).
Given the evident ease with which conceptualizations of causality arise in the
professional communities, and given the impact of those conceptualizations upon treatment, it is
important to understand the extent of support for any claim of causation. It is equally important
to understand the variables that contribute to the rise of any given worldview of causation
because those variables may well be unrelated to research evidence that would confirm or
disconfirm the model. This study will explore the social and environmental influences upon the
professional’s worldview development regarding the etiology of abnormal behaviors and how
these variables influence treatment practices.

4
Chapter 2
“Chemical Imbalance” – The Biological Model
Models
We attempt to make sense of the puzzle of psychopathology by creating models of its
development. This process often begins serendipitously and contributes to the evolution of
understanding the etiology of mental disorders. These models then lead us to efforts at treatment
(Wilson, Nathan, O’Leary, & Clark, 1997). One such example is the treatment of schizophrenia.
Scientists observed patients with Parkinson’s disease who exhibited delusional and hallucinatory
behaviors when exposed to excessive levels of dopamine (Carver, 2000; Woodruff, 2005).
Antipsychotic medications such as Risperdal, Zyprexa, Haldol, and Thorazine, thought to block
dopamine receptor sites, are now primary forms of treatment for positive and negative symptoms
of schizophrenia (Bank, 2005; Hertzman, 1992). Another example, behavioral in nature,
occurred when Ivan Pavlov discovered fundamental conditioning processes by way of trying to
unveil the secrets of the digestive system (Fredholm, 2001). Today, these conditioning processes
provide a basis for perspectives on the etiology and maintenance of anxiety disorders and are
utilized as effective behavioral treatment interventions for a variety of anxiety disorders (Mineka
& Zimbarg, 2006; Mackillop, 2005: Machulda, 1998).
It follows, that once the etiology of a disorder is thought to be understood, the most
effective treatment for such disorder is suggested by that theorized cause. What does not follow
is a global generalization and rigid application of this logic. There is good evidence to show that
biological interventions can be helpful in dealing with mental health problems associated with
environmental influences just as there are cognitive behavioral interventions that are
demonstrably helpful in dealing with symptoms of disorders that are biological in origin. For
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example, it is evident that anxiolytics such as Zanax, Ativan, or Valium, are proven effective
biological treatments of symptoms associated with PTSD (e.g. anxiety, increased heart rate,
hyper vigilance, etc.), an environmentally rooted disorder, while cognitive behavioral therapy
techniques are helpful in managing delusional and reclusive behaviors in the schizophrenic
patient (Butler, Chapman, Forman, & Beck, 2006; Hammer, Robert, Frueh, 2004; Maryasti &
Pascal, 2004; Andreas, Verena, Dirk, Michael, Elmar, Birgit, Julia, Michael, & Joachim, 2005).
Nevertheless, there is clear and convincing evidence that chemical treatment of mental health
disorders has escalated exponentially in recent years (Pincas et al, 1998; Angell, 2000;
Glenmullin, 2000; Korcok, 2002; Good, 2003; Edwards, 2003; Vaczek, 2004; Bloice, 2005).
This gives rise to a credible postulate that an increasingly popular belief system within the
mental health community is that many mental health disorders have a large biological/chemical
basis for existence.
Biological Causation
The contemporary biological model of abnormal behavior assumes that the principal
causes of, and the most likely effective treatments for, abnormal behaviors are biological
(Wilson et. al, 1997; Carver, 2000; NAMI, 2005). Biological theorists view abnormal behavior
as caused by a physical illness or injury. Most often, they point to a malfunctioning brain as the
cause of abnormal behavior, focusing particularly on problems in brain structure, brain
chemistry, or genetic makeup (Mesulam, Human, Hobson, & Silvestri, 1999; Schwartz, 1999).
The diagnostic task of defining an organic contribution to the etiology of abnormal
behavior involves two basic steps: 1) identifying a specific organic factor based on evidence
from history, physical examination, and/or laboratory tests; and 2) judging the factor to be
etiologically related to the behavioral disturbance (Reid, Balis; Sutton, 1997).
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Structural brain imaging techniques, such as Computed Axial Tomography (CT Scan – a
form of advanced X-ray technology) and Magnetic Resonance Imaging (MRI - a spectroscopic
technique used by scientists to obtain microscopic chemical and physical information about
molecules), are at times touted as preferred methods in psychiatric diagnosis (Sadock & Sadock,
2000). However, when unusual brain structures or activity are observed in a person who exhibits
overt abnormal behavior, it is unclear whether the brain abnormalities cause, are caused by, or
are unrelated to the overt behavior. It is also possible that some third factor, or set of factors,
caused both the overt abnormal behavior and the unusual brain structure noted on testing. Yet,
such correlational data, when reported by researchers, may be misinterpreted as evidence of
causation.
It is important to point out that biological abnormalities are known to cause some
abnormal behaviors. For example, structure changes to the cerebrum may result in dementia.
Dementias are typically classified according to the general brain areas involved and include
cortical changes [Alzheimer’s disease, Pick’s disease], subcortical [Huntington’s disease,
Parkinson’s disease], and axial [Wernicke-Korsakoff syndrome] (Heilman & Valenstein, 1979).
There is universal agreement that other disorders such as Down’s syndrome and Autism are the
result of biological abnormalities. The same is true for other disorders such as those attributable
to brain tumors, intracranial infection, and toxins (e.g., lead exposure). However, many other
disorders (e.g., depression, anxiety, ADHD, schizophrenia) are typically of unknown origin. In
such cases, it is tempting to make unwarranted attribution to unobserved structures or functions
of the central nervous system. Skinner (1974) labeled this phenomenon the “conceptual nervous
system” as if to point out its illegitimacy. Skinner termed the CNS a “dumping ground” where
the cause of any unexplained abnormal behavior is hypothesized to lie.
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Although computerized brain-imaging technologies promise to open new doors in the
study of the gross (large-scale) anatomy and function of the human brain, it is microscopy that
contributes to the analysis of the cellular structure and, more recently, the cellular function of the
nervous system. This particular means of investigation has fueled speculation that various
disorders are due to chemical imbalances in the brain.
The brain is estimated to be made up of approximately 100 billion nerve cells, called
neurons, and thousands of billions of support cells, called glia (Comer, 2001). Researchers into
brain anatomy have speculated that there may be a connection between psychological disorders
and chemical exchanges between neurons. A tiny space, the synapse, separates one neuron from
the next.

Hypothetically, when a thought, feeling or behavior occurs, chemicals called

neurotransmitters are released and travel across the synaptic spaces to the receptor sites of other
neurons. Those who subscribe to the biological causation worldview theorize that a given
behavioral problem may be the result of too little or too much of one or more neurotransmitters
reaching the receptor sites.

Although there is no reason to believe that such a chemical

imbalance could not cause disordered thoughts, feelings and overt behaviors, the exact
mechanism and processes remain unknown. It is worth noting that there is little evidence that
directly supports this theory (Antonuccio, Danton, DeNelsky, Greenberg , & Gordon, 1999;
Wyatt, 2003).
A branch of biological causation theory holds that abnormal activity by certain
neurotransmitters is associated with, and may cause specific behavioral disorders such as
depression and anxiety (Gershon & Reider1992; Robert, Aubin, & Darcourt1999). This belief is
built upon a top-down reductionistic analysis of abnormal behavior, which reduces complex
social interaction and other behaviors to activity at the cellular level (Kohn, 1984). This at times
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leads to illegitimate “explanations”. For example, if a child is given methylphenidate (Ritalin)
for hyperactive behavior and the family then reports improved behavior, then it is
(reductionistically) assumed that the drug’s dopamanergic effect (Plomin, 2002) substantiates an
underlying brain chemistry abnormality which was casual for the hyperactive behavior. This
style of deductive reasoning is also erroneously applied to use of other drugs that are prescribed
for other behaviors, such as anti-depressants for mood disorders (Nierenberg, McLean, Alpert,
Worthington, Rosenbaum, & Fava, 1995).

Efficacy of Psychotropic Medications
Treatment practices are often a product of research driven by sourcing the etiology of the
problem. An important issue relative to the biological causation worldview is that a review of
the literature reveals that there is less evidence of effectiveness for biological treatment of mental
health issues than one would suppose. A number of meta-analytic reviews have revealed that
evidence for effectiveness of medications is scarce, a surprising finding given the frequency with
which medications are prescribed (Khan, Leventhal, Khan, & Brown, 2002; Kirsch & Sapirstein,
1998; Sommers-Flanagan & Sommers-Flanagan, 1996).
In a meta-analysis published in 1998, Kirsch and Sapirstein compared the mean effect
size changes in symptoms of depression across 19 double-blind studies assessing the efficacy of
antidepressant medications. Results demonstrated that placebos accounted for approximately
75% of the improvement found in the active drug. Furthermore, the authors asserted that the
remaining 25% of improvement accounted for by the active drug was debatable, and could have
been the result of an enhanced placebo response due to the side effects that patients experience
when taking the active drugs, or other factors.
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Other factors that may contribute to inaccurate analysis of data are (1) a paucity of
double-blind methodologies, (2) failure to account for placebo effects, and (3) overgeneralization of results. For example, Kirsch and Weixel (1988) argued that placebo and drug
effects obtained in double-blind conditions are not comparable to those obtained in clinical
practice. They asserted that because clinical administration procedures do not lead people to
suspect that they might be receiving an inactive preparation, the expectations are greater for
change.
The placebo effect, in this case a sugar pill, has long been acknowledged to have the
capacity to rally healing processes (Harrington, 1999), and has been cited in many studies to
equal, if not exceed, improvement rate when compared to drug effects (Khan et al., 2002;
Sommers-Flanagan et al., 1996; Kirsch & Sapirstein, 1998). For example, Khan et al., (2002),
found that individuals who received a diagnosis of mild to moderate depression had a superior
response (e.g., self report of improved mood) to placebo than to a drug. Although Khan argued
that severe degrees of depression seemed to be more responsive to medication than placebo, they
noted that the greater change among patients with severe scores on the initial depression scale
scores may simply have reflected regression to the mean, rather than true drug effects. One
would expect exactly that from a mathematical point of view (Cronbach & Furby 1970; Rogosa
& Willett, 1983; Willet, 1994).
The methodologies of drug studies also present some problems in interpretation. First,
over-generalization of treatment effects from research participants to the general population is
frequently evident. Research participants usually must meet stringent exclusion and inclusion
criteria and are not representative of the population of individuals with specific disorders (Kahn
et. al, 2002). For example, Nierenberg, et al. (1995) assessed early non-response to the anti-
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depressant fluoxetine (Prozac) as a predictor of 8-week outcome. They reported that patients
were excluded from the study if they had: failed to respond to any antidepressant therapy during
the current episode; had another Axis I disorder; experienced any serious medical illness;
presented with significant lab tests (CBC, urea nitrogen, creatinine, electrolytes, plasma glucose,
liver function, thyroid, etc); were receiving anticoagulants; had a positive drug screen; reported
suicidal ideation,; “ever” received CBT or ECT; were pregnant or lactating women; were those
of childbearing potential who were not using contraceptives or if they had responded to placebo
during a 2-3 week “single-blind placebo run-in period”. It is likely not generally known outside
the drug research community that exclusion of potential subjects such as those is standard
practice in psychotropic medication research studies. Zimmerman (2004) suggests that there is
much variability in the generalizability of antidepressant efficacy trials (AET). Subjects treated
in AET’s represent only a minority of patients treated for major depression disorder (MDD). He
further states that since the inclusion and exclusion criteria used to select subjects for
participation in AET’s vary from study to study, it is unknown how much impact different sets of
exclusion criteria have on the representativeness of subjects treated.
Of special interest for this research is that in most drug studies there is a practice called
placebo run-in or “washout” group factored into the design (Leutcher, Cook, Witte, Morgan, &
Abrams, 2002; Lydiard, Steiner, Burnham, & Gergel, 1998; Nierenberg et al, 1995; Londborg,
Wolkow, Smith, DuBoff, England, Ferguson, Rosenthal, and Weise, 1998; Pohl, Wolkow, &
Clary, 1998; Sommers-Flanagan & Sommers-Flanagan, 1996). A given rationale for this practice
appears to come from a number of studies performed to determine how to separate placebo and
true clinical responses to antidepressants. Results are reported to indicate that antidepressant
placebo responses occur early and are of short duration, whereas true drug responses occur later
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and last longer (Laurie, 1996; Womack, Potthoff; & Udell, 2001;). Using a washout period is
certainly logical and intuitively compelling in efforts to minimize placebo effect. However, this
process impacts overall validity of the true drug effect by minimizing the generalizability of the
sample size and therefore erroneously exaggerating efficacy results.
After enrollment in the study, all potential subjects are given a one to three week clinical
trial of placebo (single-blind) treatment. Those subjects who respond favorably to the placebo
treatment are then excluded from the remainder of the study. Thus when the remaining subjects
are divided into two groups (drug v. placebo) results suggesting a higher drug effect when
compared to placebo is exaggerated. Conclusions such as “sertraline was safe in reducing panic
attacks” (Londborg et. al, 1998), or “sertraline (Zoloft) is an effective and well tolerated
treatment for patients with panic disorder” (Pohl et al, 1998) or “paroxetine (Paxil) was
significantly more efficacious than placebo” (Lydiard et al, 1998) are then often found in
publications targeted at professionals. More troubling is that the message of drug efficacy
presented to the public by the pharmaceutical industry in direct-to-consumer advertising, is often
accepted unwarily by the consumers of psychotropic medication.
Whether treatment is a pharmacologically inert pill or a chemically arranged Serotonin
Selective Reuptake Inhibiter (SSRI), or some other psychotropic drug, the recognition of its
symbolic value, expectancy effects and its power as a conditioned stimulus seem to be
undervalued and regularly ignored (Khan, et al. 2002; Montgomery & Kirsh, 1997).

Side Effects of Psychotropic Medication
In a world where medications are increasingly being prescribed as treatment for mental
health disorders, a patient must consider the balance between the drug’s benefit and its negative
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side effects. Side effects also have implications for interpretation of studies of medication
effectiveness. For example, the most common side effects for anti-depressant and anti-anxiety
psychotropic medications include anticholinergic effects such as blurred vision, dry mouth,
urinary retention - which can require catheterization in order to facilitate voiding, constipation,
and sexual dysfunction. An interpretation difficulty arises, then, when in double-blind, placebo
controlled studies of efficacy subjects in the placebo group fail to experience any of these wellknown side effects and as a result become less than blind to their experimental condition.
Similarly, those subjects in the control group become aware of their condition by experiencing
side effects it then becomes difficult to extract true drug effect from expectancy effects.
Aside from the difficulties that side effects present in interpretation of research results,
there are clinical concerns any time that such medications are used. Anticholinergic effects may
be especially significant in treating elderly patients who are at increased vulnerability to side
effects such as bradycardia, gastrointestinal intolerance, weight loss, and increased confusion.
However, these side effects are often “balanced” by potential for individual improvement in
quality of life. Other side effects include nausea, dizziness, headache, tension, sedation, weight
gain, postural hypotension, and more (PDR, 2004).
The anti-psychotic medications, also referred to as neuroleptics or major tranquilizers,
may have serious, life threatening, side effects.

Anti-psychotics have calmed the positive

symptoms of schizophrenia (delusions and hallucinations) but this calm may be synonymous
with sedation.

Patients are often heavily sedated, chronically thirsty, dry mouthed, and

motorically out of control. Anticholinergic side effects may include disorientation, agitation,
hallucinations, fever, seizures, stupor, and coma (PDR, 2004).
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At times the anti-psychotics also induce side effects similar to anti-depressants and antianxiety medications such as blurred vision, constipation, and urinary retention. The list goes on incontinence of both bowel and bladder, drooling, orthostatic hypotension, gynecomastia
(enlarged breasts – male and female), galactorrhea (lactation of the breasts – male and female),
sexual dysfunction, significant weight gain, sedation, skin rashes and photosensitivity,
epileptogeneic effects (seizures), cardiotoxicity, neuroleptic induced acute dystonia (abnormal
movements reflecting slow sustained muscular contraction, may involve trunk, neck, jaw, mouth,
eyes, and which can be painful), neuroleptic induced parkinsonism, masked facies, rigidity,
bradykinesia, shuffling gait, stooped posture, also known as the “Haldol Shuffle”, neuroleptic
induced acute akathisia (intense sensation of restlessness), neuroleptic induced tardive dyskinesia
(abnormal, involuntary, irregular movements which may be irreversible), tremor, and neuroleptic
malignant syndrome (severe muscle rigidity, elevated temperature, diaphoresis, dysphagia,
incontinence, mutism, elevated or labile blood pressure, death) (PDR, 2004; American
Psychiatric Association, 1994). Taking into consideration that studies designed to generate
percentage of prevalence for these side effects have proved non-generalizeable to the population
makes determination of the rate of occurrences, as well as the degree of human debilitation
impossible to quantify. The potential for both good and ill effects of anti-psychotics exists, and
their use and dis-use is understandable.
Factoring in that the prescribing of medication has shown significant growth (Balis et al.
1997; Sturm et al., 1995); medication compliance is often problematic for care providers.
Studies have noted that medication non-compliance is often related to poor treatment outcome
and a common reason for non-compliance is reported to be the side effects (Schwenk, Evans,
Laden, Lewis, 2004).
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As medication compliance remains an obstacle marketing efforts of treatment facilities
and pharmaceutical companies have attempted to address the problem.

In one brochure

produced by St. Paul-Ramsey Medical Center titled A Way To Recovery, Use of Psychiatric
Medications it is stated that “medications are needed to become well” and “medications are
needed to stay well.” There is no mention of potential harm or alternative treatment strategies.
Monmaney (1999) suggests the relaying of information to the public at large regarding potential
dangerous effects of drugs is often delayed because when problems do emerge, the
pharmaceutical companies and drug proponents initiate a vigorous strategy of defending the
drug.
One example of such delay involved risperidone also known as Risperdal. On July 21,
2004 Janssen pharmaceutical company mailed out an important correction of drug information to
all health care providers. This correction pointed out that the Food and Drug administration’s
Division of Drug, Marketing, Advertising, and Communications (DDMAC) had asked Janssen
Pharamceutica Products to contact health care providers because of a “recently” received
warning letter concerning the pharmaceutical company’s promotion of Risperdal. The warning
letter concluded that Janssen disseminated a Risperdal Dear Health Care Provider (DCHP)
packet insert dated November 10, 2003 that omitted material information about Risperdal,
minimizing potentially fatal risks, and made misleading claims suggesting superior safety to
other atypical anti-psychotics without adequate substantiation, which was in violation of the
Federal Food, Drug and Cosmetic Act (Mahmoud, 2004). Eight months passed before this
information was communicated to care providers, over half of a fiscal year in sales.
Although the Food & Drug Administration (FDA) is the primary entity empowered to
police the dangerousness of medications being released to the public, only 4% of the FDA’s
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budget is allocated to monitoring side effects once drugs have been approved (Monmaney,
1999). FDA Commissioner David Kessler revealed in 1993 that only about 1% of serious events
[side effects] were reported to the FDA (Glenmullen, 2000).
An increasing concern is the treatment of childhood behaviors as biological “disorders”
in need of medication (Fisher & Fisher, 1996). Use of psychotropic medications with children
has not been tested sufficiently to show they are safe or effective in children.
prescribed “off-label” (not FDA approved).

Many are

Nor have there been longitudinal studies to

determine any potential long-term consequences (Ramchandani, 2004; Fisher & Fisher, 1996). In
1997 over 2 million children were being treated with medication and the numbers are estimated
to be even higher today despite a near-unanimous body of literature indicating that
antidepressants are no more effective than placebos in treating depression in children and
adolescents (Edwards, 2003; Fisher et al., 1996).
On December 10, 2003 Gordon Duff, chairman of the Committee on Safety of Medicines
in the United Kingdom, advised that most of the antidepressant drugs in the selective serotonin
reuptake inhibitor group should not be used to treat major depressive disorder in children and
adolescents under the age of 18 years. The new advice follows the review of data from clinical
trials by an expert working group, convened initially because of concerns that selective serotonin
reuptake inhibitors may increase the risk of suicidal thoughts and self harm in young people. The
group concluded that the balance of risks and benefits was unfavorable for three of the selective
serotonin reuptake inhibitors (sertraline [zoloft], citalopram [celexa], and escitalopram [lexapro])
and that there was insufficient evidence to support the use of a fourth, fluvoxamine [luvox]
(Ramchandani, 2004).
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The number of American children diagnosed and medicated for attention deficit
hyperactivity disorder (ADHD) more than quadrupled in the 1990’s (Tanielian, Marcus, Suarez,
& Pincus, 2001). One might expect these numbers with a newly diagnosed disorder; however
the disorder has been articulated for three decades. Thirty years ago ADHD was diagnosed
mostly in young boys who had attention problems such as difficulty staying in their seats or
waiting their turn. Now it has spread from boys to girls and to all age groups, including adults.
Although behavior modification, parenting education and focus training are effective treatment’s
of ADHD behaviors, especially with early intervention, psychiatry continues to assert that
medication yields the most success (Edwards, 2003; Handen, Feldman, Lurier, & Murray, 1999;
Perring, 1997).
Moreover, some experts dispute the contention that ADHD should be termed a
“disorder”. Medical sociologist Peter Conrad of Brandeis University believes that the increased
use of drugs is an example of how Americans have come to treat normal differences among
children and adults as evidence of disease (Edwards, 2003).
In summary, biological causation is somewhat synonymous with the chemical imbalance
hypothesis. The essential postulate is that all behaviors are rooted in the quantity chemistry of
neurotransmission (our biology).

It is thought you either have too much or not enough

neurotransmitters and medication serves as a correction factor in the equation. However, when
taking into consideration questionable drug efficacy studies with a continued significant rise in
the prescribing of psychotropic medications, it is of interest to explore if there are other variables
influencing the theory of biological basis for behavior.
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Chapter 3
Social Influence
What follows is discussion of several influences that are believed to contribute to the
development of biological causation worldviews of many mental health professionals. The
discussion is focused upon ways in which mass media, pharmaceutical companies’ advertising,
guild influences, insurance industry interests and layperson preferences, individually and
collectively, may lead to the practitioner’s adoption of a biological causation worldview.
Pharmaceutical Industry Influence
Is academic medicine for sale? Marcia Angell, Editor in Chief of The New England
Journal of Medicine (2000), asked that question in an editorial prompted by a study on
antidepressants. She reports that many authors have financial links to drug companies, links so
numerous that there is not enough space to list them all in the journal. Angell acknowledged
violations of journal policy which prohibits review articles and editorials written by an author
with a financial interest in his or her topic. Moreover, Angell (2000) postulates that drug
companies are increasingly promoting diseases to fit drugs and that common people are coming
to believe they suffer from serious ailments.
The pharmaceutical industry has gained much by its efforts at convincing professionals
and laypersons that biology is the cause of abnormal behaviors. According to the April 2003
issue of Pharmacy Times, the anti-psychotic, Zyprexa and the anti-depressants Zoloft and Paxil
were sixth, ninth and tenth respectively, among all drugs, in 2002 overall sales, generating
almost $8 billion dollars in revenue for the pharmaceutical industry that year. Although
Neurontin is a medication that is FDA approved only for the treatment of seizures and pain, its
common use for mania made it number twelve in overall sales, with over $2 billion in sales. The
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anti-psychotic, Risperdal, followed at number 15 with $1.8 billion in sales, and the antidepressant Celexa ranked twentieth with $1.5 billion in sales. Sales growth in 2002 ranged from
10.7% (Paxil) to 39.9% (Celexa). According to Pharmacy Times, advertising to consumers and
physicians was a driving influence in raising awareness about anxiety and depressive disorders
(Vaczek, 2003). This particular success in advertising has significant implications. Research
demonstrates that when a consumer responds to an “ask your doctor” campaign, over-prescribing
of medication occurs even when the patient presents with minor symptoms (Kravitz, Epstein,
Feldman, Franz, Azari, Wilkes, Hinton, & Franks, 2005).
Pincus (1998) reported that psychotropic prescriptions increased 20% from 1985 – 1994
in the United States. During this same time period prescriptions for stimulants tripled and those
for mood elevators doubled to 20 million. In the span of one decade (1990 – 2001) production of
Ritalin increased 700%, which was also consistent with increased advertising. In Pediatrics the
number of full-page advertisements for stimulants doubled from 1990 – 2000 (Wyatt, 2003). In
1996 USA consumers were spending $3.8 billion a year on anti-depressants.

That had nearly

tripled to $9.9 billion by 2001 (Millenson & Shalowitz, 2005).
Pfizer, a well-known pharmaceutical company, includes in its mission statement, “We
dedicate ourselves to humanity's quest for longer, healthier, happier lives through innovation in
pharmaceutical, consumer, and animal health products” (Pfizer, 2003). Pfizer describes a budget
of $5.3 billion for research and development (R&D) as a path to its mission (Pfizer, 2003).
However, United States R&D discovery of new molecular entities (medicines) is significantly
below global standards and generated revenue remains sizeable relative to profit versus R&D
budget (Light & Lexchin, 2005).
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Funding resources are often channeled to the development and marketing of what
industry critics term “me-too” drugs and the practice of “evergreening” (Bloice, 2005). Me-too
drugs refer to medications that come on the market to compete with a new drug that has taken
market prominence – and profits. Rather than develop a new drug to tackle a troubling medical
condition, corporations develop drugs to compete with market leaders. “Evergreening” involves
employing the same basic research used to manufacture one drug in order to make available a
new, slightly different one. When the patent on the original drug is about to run out and other
companies are preparing to launch generic, cheaper versions, the new version is promoted
through direct advertising to physicians and consumers.
In a submission for public hearing in 2005, Donald W. Light, PhD, University of
Medicine and Dentistry of New Jersey, and Joel Lexchin, MD with the School of Health Policy
and Management of York University wrote, “The most objective research on corporate R&D in
the United States reports that just under 12 percent of domestic sales is devoted to R&D, not the
much higher figures cited by industry leaders. Thus, contrary to what the pharmaceutical
industry claims, in relative terms, R&D spending outside the U.S. is more intense and more
productive than in the U.S.” (Pharmacy Times, 2003; Light & Lexchin, 2005). Typically a new
drug’s sales increase by no more than 14 percent per year, however sales of drugs heavily
advertised to consumers surge by more than twice that amount, on average 32 percent a year
(Good, 2003; Pincas, Chang, Tol, & Hubert, 1993).
Mass Media
Consumers are reached by television, newspapers, magazines, medical newsletters,
billboards, radio, pamphlets, and mailings of various kinds. With approximately 4800 journals
indexed on MEDLINE (2005), containing more than 9 million abstracts, the sheer mass of
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emerging research is overwhelming. Unfortunately, there is a gap between the wealth of
expanding information and the quality of the public’s health knowledge and practice, partly
because of the difficulty of dispensing this information to the public.
The editors of the New England Journal of Medicine noted that "the problem of
[communicating health] is not in the research itself but in the way it is interpreted for the public"
(Angell & Kassirer, 1994). We rely on the skills of journalists to facilitate the flow of reliable
and valid medical research to the public at large. Assuming that a journalist is reporting medical
information accurately, there are still several barriers to improving the informative value of
medical journalism such as lack of time, space and knowledge; competition for space and
audience; difficulties with terminology; problems finding and using sources; as well as problems
with editors and commercialism (Coulter, 2003). Given that public perceptions continue to be
greatly influenced by the media it seems necessary to assure the accuracy of disseminated
information (Wakefield, 2003; Mutz, 1989).
The media strive to meet the increasing public demands for health information. Often
health journalism goes far beyond the available data. For example, a headline in Time appeared
beside the picture of a stark ambiguous face with vacant eyes, that read “Suicide check:
Advances in bio-psychiatry may lead to lab tests for self-destructive behavior and other mental
disorders” (Gorman, 1994). The article described the “promising development” of a potential
lab test for suicide. It pointed out that the vast percentage of people who commit suicide show
brain changes at autopsy. However, what was missing was the percentage of people who never
attempt suicide who possess those same brain changes. The article further emphasized the “hot
new field of biological psychiatry” and that what once was the purview of priests and analysts, is
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now a frontier for psychiatrists who use “blood tests, brain scans and spinal taps” to distinguish
among types of depression and schizophrenia.
Beyond health related information media reports contribute to an expanding
biologicalization of all elements of human experience. For example, the National Geographic
(1995) published an article titled, “Quiet Miracles of the Brain”, where former National Institutes
of Health pharmacologist Candice Pert described emotions as, “…neuropeptitdes attaching to
receptors and stimulating an electrical charge on neurons.” In that article Pert did not account
for the influence of verbal communities that teach us to label emotions as we do. It is plausible
that some basic emotions such as fear and rage amount to little more than genetically
programmed responses. But the vast majority of emotions labeled - embarrassment, anticipation,
shyness, perplexity, etc., are likely learned, taught to us by the verbal community (Skinner,
1974). We have to be cautious in reading the media as they report more on the biological basis
of behavior as this practice can shift perception in an extreme direction.
Newsweek (2003), a popular magazine with a circulation of 4 million worldwide and 3
million in the United States alone, (and a readership likely well beyond that) reported how an
amygdala, “…perceives a threat…” However, amygdala’s do not explain why one person may
scream at the sight of a spider, while another keeps spiders as pets. It is in volume that these
styles of statements are disseminated to the public. If one believes the criticisms of the
biological causation model previously discussed, then it is logical to conclude that articles in this
format could be construed as misleading the majority of readers, given that they are usually not
equipped to think critically about behavioral sciences.
Professional Guild Influence
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Abnormal behavior has not always been “medicalized.” For example, in the early 1900’s
child abnormal behavior was considered a social problem. Some professionals hypothesize that
governmental forces pressured the medical community to re-conceptualize the origin of deviant
behavior in an effort to apply more effective techniques of reform (Rafalovich, 2001). In
Identifying Hyperactive Children, a book claimed to be the “first empirical analysis of the
process of medicalization”, Conrad (1976) examined the process by which medical professionals
first problematized childhood deviance.
What is significant, however, is the expansion of the sphere where
medicine now functions as an agent of social control. In the wake
of general humanitarian trend, the success and prestige of modern
medicine, the increasing acceptance of deterministic social and
medical concepts, the technological growth of the twentieth century
and the diminution of religion as a viable institution of control, more
and more deviant behavior has come into the province of medicine
(Conrad, 1976).
Guild issues, particularly those of organized psychiatry, have played a part in the history
of how we have come to medicalize abnormal behaviors.

Between 1970 and 1980 the

percentage of medical school graduates choosing psychiatry as a specialty dropped by more than
half, from 11% to 5% (Nelson, 1982). As a result of that decline organized psychiatry undertook
an effort to recruit more medical school graduates into the field. In the 1980’s psychiatrists held
conferences, such as one in San Antonio, to outline a plan of action. The consensus among those
attending was that psychiatry had lost esteem (perhaps due to visibility of avante guarde
“treatment” of the radical 1960’s emphasis on family practices etc.) and that it would need to
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become more “biological” if it was to regain lost esteem and influence (Nelson, 1982). To
become more medical, it was necessary for psychiatry to conceptualize more and more disorders
as biologically determined, so as to become more closely identified with scientific methods and
at the same time move away from non-medical explanations.
In 1988 two high profile members of the American Psychological Association authored a
paper which they titled “Psychiatry Declares War on Psychology”. They describe numerous
kinds of evidence for the “war”, including that psychiatry had, over the past decade, attempted to
“medicalize” itself, by suggesting that if mental health care is defined as exclusively “medical” it
would follow that psychologists, untrained in “medical matters”, would be incompetent to
diagnose or treat such problems. Exceptions would be made for psychologists working under the
direct supervision of a psychiatrist.
At the same time that psychiatry was becoming increasingly medical, organized clinical
psychology was attempting to expand various aspects of its scope of practice. These included
hospital admission privileges (APA Practitioner Focus, 1990), the right to be reimbursed by
Medicare without supervision by a physician (Buie, 1989), and prescription privileges (Seaman,
1997).
In 1988 the American Psychiatric Association’s President-Elect, Paul Fink, wrote that
Psychologists and other non-Psychiatrists, “Don’t have the training to make the initial evaluation
and diagnosis…are not trained to understand the nuances of the mind…” (Tanney, 1988). A
month later Melvin Shabshin, Medical Director of the American Psychiatric Association,
testified to the New York state legislature asking, “Do the substantial and inevitable risks to the
quality of patient and medical care in (NY) hospitals outweigh the dubious, purported benefits
associated with hospital privileges for these non-physician practitioners?” (Welch, 1988).
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Although organized psychiatry minimized the training of clinical psychologists throughout the
1980’s while organized psychology was able to demonstrate the profession’s ability to diagnose
and treat mental health problems, with equal efficacy of practicing physicians and psychiatrists
(Tanney, 1988, Buie, 1989 & Youngstrom, 1990).
In 2002, former American Psychiatric Association President Ronald E. Fox, in reference
to psychiatry’s opposition to psychology’s prescription privileges, noted that the medical
profession has always resisted intrusions on its “turf” by attempting to medicalize assessment
and treatment techniques and by holding that non-physicians are ill-trained to accomplish those
activities (Fox, 2002). The case has been made for caution in the psychologist’s pursuit of
prescription privileges.

Some suggest that psychologists should maintain their focus and

expertise in assessment and psychosocial intervention, particularly thought to be the most
effective form of treatment for mental health problems (Amerikaner, 1997). Regardless of where
one falls in that debate, this context suggests that organized medicine and organized psychiatry
have fought a “turf” battle by conceptualizing psychiatric disorders as biologically caused.
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HMO and Insurance Interest
In selecting the treatment modality to be used, the relative effectiveness of drug and nondrug therapy is not the only criterion. Cost is certainly a consideration (Valenstein, 1998). With
health care costs rising, health care reform is an urgent issue facing the United States today. One
effort to solve this growing problem is the Health Maintenance Organization (HMO). Millions
of Americans have found their health insurance has changed, as they have been moved into
HMOs and away from more traditional health insurance programs. Many of these HMOs are
for-profit organizations, creating an uneasy relationship between business and health care,
especially mental health care (Taylor, 2003). It has been established that in the short term
medication is less costly than psychotherapy to insurers by about 50% (DeRubeis, Gelfand,
Tang, & Simons, 1999).

Seizing upon that fact, and ignoring the long term benefits of

psychotherapy, the insurers appears to accept the use of medication over therapy and general
medical care, as opposed to specialty mental health care as primary treatment for mental health
problems (Sturm & Wells, 1995).
Moreover, administrators of managed care programs have argued that psychotherapy is
"enhancement not treatment" (Valenstein, 1998). This mode of thinking is illustrated in fee per
service reimbursement. The amount of money allotted to reimburse psychotherapists for each
session is, in some instances, only one-half of their customary charge. Many health plans pay 80
percent of the average fee of physicians who dispense antidepressants, but only 50 percent of a
psychotherapist's normal fee.
However, the industry position is contradictory to empirical findings. Several metaanalyses of studies covering thousands of patients comparing medication vs. therapy found
remarkable consistency in support of the perspective that psychotherapy is as effective as
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medication for treatment of depression and more effective than medicine in the long term
(Jacobson & Hollon, 1996; Hollon, 1996, & Antonuccio, Danton, & DeNelsky, 1995). Yet there
has in recent years been an attempt on the part of healthcare providers to limit the number of
psychotherapy sessions much more so than the number of office visits for medication refills
(Valenstein, 1998). The industry will support medication treatment, a biologically based
intervention that, arguably does the same thing as psychotherapy – “enhance” an individual’s
life.

Layperson Preference
Sylvia Plath was a young promising author and poet said to have had a “mental
breakdown” in her early college years. She wrote about the indignity she felt for her suffering of
the mind, “… if only something were wrong with my body it would be fine, I would rather have
anything wrong with my body than something wrong with my head.” (1966). Plath committed
suicide at the age of 30.

Unfortunately, many who suffer similar experiences share her

preference. The diagnosis of a mental “illness” is not a welcomed label and can be viewed as an
added burden, often linked with job loss, relationship breakdown, and social rejection.

A

psychological diagnosis often carries a stigma similar to that of AIDS and cancer (Wahl, 1999).
Many believe that a psychological problem has an element of personal culpability, implying that
a person is weak or has not tried to overcome his problem (Link, Struening, Rahav, Phelan,
Nuttbrock, 1997; Wahl, 1999).
Assumed communication difficulties and social non-productivity reinforce the tendency
to discriminate against those with mental health problems. Also, among the general population
abnormal behavior is associated with dangerousness. The rare but widely publicized violent
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incidents associated with mentally ill patients fuels that fear.

Images of stigma, non-

productivity, and violence contributed to the movement among laypersons toward re-classifying
mental illness as a physical disease rather than a “character flaw” (Hill, Steinhauer, Zubin, 1986;
Astrid, 1998; Begleiter & Porjesz, 1999; Farnham & James, 2000).
The National Alliance for the Mentally Ill (NAMI), a broad-based consumer advocacy
group strongly advocates the position that mental illness essentially is a biological brain disorder
(NAMI, 2005).

With a paid membership of 80,000 and a website (www.nami.org) that

reportedly receives 14,000 hits a day, NAMI’s literature emphasizes that the theory of biological
causation is an effective tool in the fight against the stigma of mental illness. NAMI asserts
mental illness is not the result of personal weakness, lack of character or difficult upbringing.
Critics suggest that NAMI, which is comprised mainly of parents of the mentally ill, simply
wants to shift the notion that mental illness is a biological brain disorder rather than the
responsibility of child-rearing flaws – or even abuse (Donahue, 2000).
Daniel Fisher, MD, who recovered from schizophrenia to become a psychiatrist and now
heads the National Empowerment Center, believes that seeing mental illness as a biological
disorder is the “easy way out”. He postulates that blaming the brain is much easier than looking
at individual issues, taking personal responsibility or accurately interpreting the realities of social
situations and context (1999).
As the divergence between treatment modalities (i.e., biologically based treatments vs.
therapy) moves on, a paradoxical scenario results for the consumer. First, viewing mental illness
as biologically based alleviates shame and reduces stigma.

It shifts the responsibility for

recovery (and relapse) to the treating physician. On the other hand, this same process can
inadvertently remove the consumer from one important element necessary for regaining or
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sustaining mental health – a sense of internal locus of control (Michelson, Bellanti, Testa, &
Marchione, 1997).
In addition to matters of guilt reduction and personal control, the layperson also is
inundated with direct-to-consumer advertising by pharmaceutical companies. Advertisements
often reinforce the message of biological causation. The billions spent on advertising each year
is evidence for its efficacy (Edwards, 2003; Good, 2003, Pharmacy Times, 2003; & Bloice,
2005). It is a common occurrence for United States television viewers to be subjected to pitches
for pharmacological interventions that will ease their “illness”, often encouraging the consumer
to, “Be sure to ask your doctor if this medication is right for you.”
Laypersons have little exposure to the empirical evidence about drug efficacy and safety.
They depend on information that amounts to nothing more than drug company promotional
material, or at the very least, is information that is filtered and shaped by drug companies
(Valenstein, 1998). A model of direct-to-consumer advertising holds that: (1) advertisement
exposure raises consumer awareness of conditions and treatments; (2) increased awareness
motivates patients to seek medical care and request drug therapy; and (3) patients’ requests lead
to increased prescribing. This leads to the over prescribing of unnecessary, expensive and
potentially harmful anti-depressant medications (Kravitz et al, 2005).
The patient’s preference for a non-stigmatizing, responsibility-alleviating, responsibility
shifting view of mental illness fits neatly with social influences of the drug industry and has in
recent years been magnified by direct-to-consumer advertising. The downside is that the causes
of patients’ abnormal behaviors may be overlooked, at least to the extent that the causes are
located in patients’ environmental and learned histories.
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Chapter 4
Persuasion
Persuasion and Attitude Change
A great deal has been written about the topics of persuasion and attitude/belief change
(e.g., Allen & Preiss, 1998; Cialdini, 2001; Dillard & Pfau, 2002; Perloff, 1993). The majority
of these sources are devoted to fields other than the attitudes of mental health practitioners. For
the most part, the literature on attitude change has focused upon changing beliefs concerning
political matters, consumer products and guilt or innocence of defendants in criminal and civil
cases. EBSCO host searches revealed no results for “attitude change” or “opinion change” when
these terms were combined with any of the following: mental health, schizophrenia, depression,
anxiety or ADHD. Additional search of the literature uncovered no other relevant sources.
Despite the lack of empirical evidence relative to the mental health field and attitude
change, some fairly consistent findings have emerged regarding a number of variables that are
thought to be influential in changing attitudes and beliefs of listeners, in general. For example,
physical attractiveness of the speaker tends to exert a positive influence on message acceptance
(e.g., Cialdini, 2001; Haughtvedt, 1997; Perloff, 1993). Similarly, perceived prestige of the
speaker tends to enhance attitude change (Aronson & Golden, 1962; Berlo, Lemest & Martin,
1969; Eagly, Wood & Chaiken, 1978; Haughtvedt, 1997).
A speaker’s verbal presentation style has impact upon the listener’s adoption of the
speaker’s position. That is, a speaker’s verbal speed, intensity, choice of words and the like will
influence the resulting level of agreement with the speaker’s position (Perloff, 1993). An
extensive review of the influence of verbal style (Burrell & Koper, 1998) revealed several factors
that any speaker would do well to keep in mind: An extensive vocabulary is beneficial; use of
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declaratives, as opposed to questions, results in greater attitude change; employment of empty
adjectives (“cute,” “sweet”) degrades message acceptance as does being overly polite. Burrell &
Koper (1998) found, as well, that use of hedges (“I guess,” “kinda,” “you know”) and intensives
(“very” and other superlatives) tends to hamper message acceptance, and use of powerful
language (“it is,’ “no doubt”) is helpful in persuading an audience. Summarizing their findings,
Burrell and Koper concluded that the use of “socially powerful language” enhances persuasion
and credibility.
Systemic & Heuristic Factors
Related to research trends regarding persuasion and attitude change are contemporary
theories. Although historically audiences were thought to be passive, accepting whatever
message was brought to them, that conceptualization has changed with the emergence of the
cognitive perspective. In the past audiences were thought of as infused with information, while
in recent years the cognitive perspective has taken the approach that audiences actively process
information (Perloff, 1993). Listeners may do this in either of two styles: systemic or heuristic,
the latter also known as the elaboration likelihood model—ELM (Booth-Butterfield, 2005; Petty
& Cacioppo, 1986). When a listener is responding systemically, he or she is actively processing
what is said, is alert, is attending to details and is weighing the content that is being presented. In
contrast, when a listener is responding heuristically, he or she is more influenced by superficial
variables such as physical attractiveness and verbal style. Although research continues along
systemic/heuristic lines, it is clear from the host of variables described above, that the interplay
of listener style with both speaker style and content is an area that has much to offer researchers
in the field.
Where the biological causation model of mental disorders is concerned, any effort to
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realign the attitudes and beliefs of mental health professionals with the state of research should
give consideration to the variables described above. However, when one considers the training
and experience of front-line treating professionals, it is reasonable to assume that empirical data
would have significant impact in any presentation that is designed to change their thinking.
While heuristic factors should have some relevance for such an audience, one would hypothesize
that systemic factors, such as research data, may well exert more powerful influence simply
because most mental health practitioners (psychologists, counselors, clinical social workers, etc.)
have training histories in which research was emphasized.
However, that is not to say that heuristic factors are not at times paramount. Further, it is
not to say that non-empirical cultural zeitgeists (e.g., as shaped by factors such as advertising)
have but little influence upon those trained in behavioral and social sciences. Quite the opposite
is the case, as demonstrated earlier. Rather, the role of empirical data in attitude change ought to
be particularly important when the audience is comprised of health care practitioners, given that
their training is well-known to place emphasis upon research, albeit in varying degrees across
disciplines and training institutions. Perloff (1993) concluded that. “The research literature
strongly supports the notion that evidence enhances persuasion”. Similarly, Reinard (1988)
found that, “Evidence appears to produce general persuasive effects that appear surprisingly
stable”.
It is possible that evidence may be misperceived, or may not be “evidence” at all. For
example, when pseudo-scientific messages are employed, particularly those that contain a great
deal of scientese (scientific jargon), message persuasiveness is enhanced (Haard, Slater & Long,
2004). In any event, however, it is clear that research evidence is an important variable in the
influence process. That would likely be especially true when the audience is trained to
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appreciate and utilize research, although one would still expect a professional audience to be
influenced to some extent by heuristic variables.
Audiences tend to pay greater attention when the speaker’s message has high relevance
for them. For example, when students listened to a presentation about potential changes in
comprehensive exams, the message had greater impact if the proposed changes would affect
their exams, as opposed to exams of some future generation of students (Kerr, 2002). Similarity
(e.g., age, sex) of presenter and audience also affects change in attitude, but that factor is more
powerful if a similarity (e.g., profession) is relevant to the message presented (e.g., Perloff,
1993).
Ultimately, it would seem that a relatively sophisticated audience of mental health
practitioners would be positively influenced by research evidence. O’Keefe (1998) performed a
meta-analysis of the credibility effects of evidence and found consistent positive effects for
evidence. Reynolds and Reynolds (2002) reviewed the literature and concluded, “In summary,
the use of evidence produces more attitude change than the use of no evidence”. However,
Reynolds and Reynolds were careful to point out that recipients must be aware of the evidence
being presented, must process the evidence and must perceive the evidence as legitimate in order
for the evidence to influence the audience.
One may ask, then, what specific conditions would tend to cause a data-based message to
be favorably received. One factor appears to be the citation of sources (Fleshler, Ilardo &
Demoretcky, 1974; O’Keefe, 1998). The failure to cite relevant sources may result in changes in
the opposite direction of that desired by the speaker. That result may be even worse if no
supporting citations are cited to counter an opposing message that is supported (Reynolds &
Reynolds, 2002).
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Whether anecdotes help or harm a speaker’s efforts to bring about attitude/belief change
may depend on several factors. Some research suggests that anecdotes may be as persuasive as
statistical data when the audience is only moderately involved (Baesler, 1997). Other data
indicate the superiority of data over anecdote (Allen & Preiss, 1997). Kopfman, Smith, Ah Yun
and Hodges (1998) found that statistical evidence is more persuasive in producing cognitive
reactions in the listener, while anecdotes result in greater affective change. Probably it is wise to
use both some statistical evidence and some anecdote, with the preponderance going to statistical
evidence, in any effort to bring about attitude/belief change.
Whether evidence is accepted by the listener may also depend upon his or her prior
knowledge of the subject. Reynolds & Reynolds (2002) found that evidence is unlikely to have
impact upon an audience that lacks prior information about the subject. Perhaps that is because
an audience must perceive the evidence as legitimate, and it may be difficult to achieve that with
a completely naïve audience. Reynolds (1987) pointed out that an audience must be able to
follow a link from evidence evaluation to overall message evaluation, to achieve change in
belief.
Additional factors that influence a listener include the perception of bias in the
presentation. At least a few statements that are at odds with the speaker’s evident bias tend to
result in greater credibility of the speaker (e.g., McCroskey, 1967). However, a speaker walks a
fine line in that regard. Once a source is seen as invalid on one bit if information, his or her
credibility may be weakened on other information (Schul & Mayo, 1999). Some research has
shown that audience members whose initial position is in agreement with the speaker prefer
statistical evidence, while those who oppose the position advanced by the speaker find anecdotal
stories to be more persuasive (Slater & Rouner, 1996).
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It may be possible to present too much information. Lavasseur and Dean (1996) found
this to be the case when they examined the audience reactions to U.S. presidential candidates
engaged in debates. However, the authors acknowledged that such candidates are probably
already expected to have a great deal of knowledge and to be quick to bring forth that
knowledge. The candidates likely had more credibility to lose than to gain, a fact which may
have accounted for the effect in their study. Reynolds and Reynolds (2002) took note of the
Lavasseur and Dean findings and suggested that, “more everyday speakers may want to include
the best evidence possible because, even if the speaker does not have an obvious immediate
opponent, most sophisticated audiences are quite capable of generating counterarguments against
the claims of even the most highly regarded advocate” (p.434).
Thus, the literature suggests that a relatively sophisticated audience of mental health
practitioners would probably be most amenable to changing their beliefs/attitudes under the
following conditions: The speaker presents material in a relatively fluent manner, using a
“socially powerful” verbal style; the presentation is primarily supported by data, with citations,
and includes minimal anecdotal messages; the message is seen as highly relevant by the
audience; some mention is made of information that goes against the presenter’s evident bias;
and the presenter is careful to avoid data overkill.
With those factors in mind, the present study represents an attempt to change the beliefs
of front-line mental health professionals as regards to the evident surge in advocacy of biological
causation of mental disorders.
Research Statement
Although there is no dearth of exceptions, when the cause of a mental health disorder is
thought to be understood, typically the treatment for that disorder is pursued based upon the
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hypothesized cause (Carver, 2000, Fredholm, 2001, & Woodruff, 2005). There is evidence that
chemical treatment of mental health disorders has escalated exponentially in recent years (Pincas
et al, 1998; Angell, 2000; Glenmullin, 2000; Korcok, 2002; Good, 2003; Edwards, 2003;
Vaczek, 2004; Bloice, 2005). Therefore, it is plausible to postulate that an increasingly popular
belief system within the mental health community is that many mental health disorders are
largely biologically/chemically caused.
However, it is likely that variables such as drug company advertising as well as guild
dominance influence both perceptions of causation and scope of chemical treatment
interventions.

With closer inspection of drug efficacy research, findings are less empirically

robust than one would suppose – calling into question the emphasis that has been placed upon
the biological causation model in the past several decades. This suggests a cautionary approach
be taken in the way in which we view the causation and treatment of mental health disorders,
given the impact this can have on treatment interventions.
It is within the mental health community where the catalyst for change likely should
arise. It is these experts who are best positioned to influence social debate and public policy in
the mental health arena (Amerikaner, 1997). Current thinking in the field of attitude change and
persuasion indicates that empirical data can have a powerful influence on an individual’s
attitude/ belief system (Booth-Butterfield, 2005; Petty & Cacioppo, 1986). Therefore it stands to
reason that training such as outlined below, designed to inform listeners of the data relative to
biological causation and treatment, would have impact on the mental health professional’s belief
system. If so, a starting point for public policy revisions and change in treatment interventions
may result.
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Hypotheses

1. Mental health professionals’ reported strength of belief regarding the etiology of many
mental health disorders tends toward the biologically based.
2. Mental health professionals’ reported strength of belief regarding the etiology of mental
health disorders is amenable to change as the result of a 3 hour training program.
3. Change in belief in biological causation is associated with change in belief in five domains
(guild; pharmaceutical; layperson; HMO/insurance; empirical).
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Chapter 5
Method

The present study examines mental health professionals’ strength of belief in biological
causation of several syndromes including ADHD, unipolar depression, anxiety disorders, and
schizophrenia and whether a three hour educational program will alter their strength of belief.
This study was reviewed and approved by Marshall University’s Internal Review Board
to assure accordance with research practices and standards.
Overview
Professionals involved in the mental health field attended a three-hour training program
that reviewed the influences of the pharmaceutical industry and of organized psychiatry in
shaping worldviews about the causes of abnormal behaviors. The training included a critique of
studies often cited in support of biological causation. A pre-post survey (see Appendix I &
Appendix II) was administered to the participants in order to assess initial strength of belief in
biological causation and whether professionals’ thinking was changed as a result of the training.
Training was conducted with staff at a local inpatient, for-profit psychiatric hospital, and with
conference attendees of the West Virginia Psychological Association.

A control group

comprised of college students completed the pre-post assessment while attending a graduate
course dealing with unrelated material (statistics).
Participants
The Treatment Group consisted of 76 mental health professionals ranging in age from 18
to 63+ (see Table 1). The majority of participants (78%) had a master’s degree or higher (see
Table 2) and 52% were female and 48% were male.
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Ninety percent of the participants were identified as non-medical mental health
employees (Table 3 & Table 4) and all were recruited through standard announcements about the
training opportunity, including that continuing education was available. CE credit was not
contingent upon pre-post completion of the assessment form.
The Control Group consisted of 26 graduate and undergraduate students participating in
an advanced statistics class.

Participation was voluntary. The content of the class included no

components of the workshop. Control participants’ ages ranged from of 18 to 44 with 80%
being female and 20% male.
All subjects in both groups completed an informed consent in accordance with the Ethical
Principles of Psychologists and Code of Conduct - Principle 6.11.
Materials & Procedure
Strength of Belief Scale (SOBS) is a 38-item survey containing six domains of interest to
this research: [1] Biological Causation (General) Domain: Strength of belief in the biological
model as etiology for a range of mental health problems (anxiety, addiction, depression, ADHD,
& Schizophrenia). [2] Layperson Domain: Professionals’ perceptions of layperson preference
for biological explanations. [3] Empirical Domain: Importance of empirical data to the
thinking of professionals regarding causation of mental disorders. [4] Pharmaceutical Domain:
Professionals’ perceptions of pharmaceutical industry influence upon belief in biological
causation. [5] Guild Domain: Professionals’ views of organized psychiatry’s guild interests
upon acceptance of biological causation. [6] Health Maintenance Organization (HMO)
Domain: The HMO industry’s influence upon professionals’ beliefs in biological causation.
Each domain contains a subset of items that collectively demonstrate the strength of
belief regarding that particular category (see Appendix III). Each item is rated on a Likert-type
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scale of one (1) to six (6) with one (1) meaning “strongly agree” and six (6) indicating “strongly
disagree”. The intervening points on the Likert scale are: two (2) equals agree; three (3) equals
somewhat agree; four (4) equals somewhat disagree; and five (5) equals disagree.
The SOBS development entailed a three-fold process. First, an initial set of items was
formulated based on intuitive judgment. They were submitted to Marshall University Department
of Psychology faculty for general feedback regarding each item. Feedback consisted mainly of
editing along with intuitive perception of item relevance to the study at hand. Second, after
adjustments were made based on faculty feedback, revised surveys were completed by a small
sample of graduate students. Items that correlated weakly with other items within their specified
domain(s) were eliminated. Third, a final reliability analysis was conducted with the remaining
thirty-eight items from the treatment group data. Coefficient alphas ranged from .57 - .87 for the
six domains (see Table 6).
A three-hour training program for mental health professionals was developed.

It

reviewed the historical roots of organized psychiatry’s increasing embrace of biological
causation, and the ways in which the pharmaceutical industry has fostered that aim.
Additionally, the training reviewed and critically analyzed research often cited in support of
biological causation as well as research on drug trials methodology, drug effectiveness, and
influence of placebo effect. Each of the domains, excepting HMO, received emphasis with
regard to its connection to acceptance of the biological causation model of mental disorders. The
training was conducted in didactic style by a tenured professor of psychology who employed 90
power point slides. The presenter followed closely the Power Point presentation.
The Treatment Group participated in the training program. Prior to the beginning of the
training the participants were asked to complete the SOBS (see Appendix I), to assess their
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beliefs regarding the causes of mental illness, especially their strength of belief in biological
causation. Upon the completion of the training, participants were asked to again complete the
SOBS (see Appendix II), which contained the same items as the pre-survey with the items
randomly reordered.
The Control Group completed the survey at the beginning and again at the end of their 3
hour statistics class. They were given the same directions as the treatment group but did not
participate in the training program.
Design & Analysis
A quasi-experimental non-equivalent groups design was utilized. Paired t-tests (twotailed) were used to test for pre-post changes within each group separately.

A linear regression

analysis was conducted to evaluate whether a change in belief regarding the domains (guild;
pharmaceutical; layperson; HMO/insurance; empirical) was associated with change in strength of
belief in the biological causation domain after controlling for the effect of several demographic
variables. An alpha level of .05 was used for all tests.
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Chapter 6
Results
Individual Item Analysis
Each item on the SOBS (see Appendix I) was analyzed by assessing the pre-post mean
differences. Of the 38 item survey, 22 items indicated that the participants’ thinking in the
treatment group changed significantly post the treatment intervention (see Table 9). Of
particular interest were changes in items indicating that the participants, following training,
possessed weaker belief in issues involving claims of biological causation. For example, item
two (2) stated, Anxiety is a biological disorder. Prior to the training the mean score was 3.34
indicating a slight tendency to agree. However, post training the mean score was 4.11,
signifying that the participants beliefs had shifted towards tending to disagree (t (75) = 4.2, p
<.01).
Item twenty-one (21) stated, ADHD is a biological disorder. Prior to the training the
mean score was 2.57 indicating a tendency to agree. However, post-training the mean score was
3.79, signifying that the participants thinking changed toward disagreement (t (74) = 9.3, p <.01).
Item number 26 stated, Studies of identical twins who are separated soon after birth and
reared apart, that show fairly high levels of concordance for various mental and behavioral
disorders, provide strong evidence for biological causation of mental disorders. The training
changed participants mean rating from 2.72 to 4.14 (t (74) = 8.4, p <.01). This indicated that the
training section which critically examined the twin studies’ claims of biological causation
resulted in decreased credibility in such studies among the participants.
Item one (1) stated, Attending pharmaceutical company sponsored workshops is helpful
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for me to understand the benefits of psychotropic medication. Participants’ pre-survey mean
score was 2.68, signifying they were somewhat in agreement with this statement. However, after
the training, participants’ mean score was 4.05 signifying greater disagreement with the notion
that pharmaceutical company sponsored workshops are reliable and valid sources of information.
The training provided evidence that pharmaceutical advertising and research is inherently
confounded, largely by the financial interests of the pharmaceutical industry.
As expected and a testament to the strength of the instrument, there were no pattern of
change noted in items twenty (20), twenty-four (24), and twenty-seven (27), where participants
agreed that psychiatrists, psychologists, and counselors were well suited to diagnose and treat
mental disorders. However, mean agreement was stronger for opinions regarding psychologist
(1.97) than regarding psychiatrist (2.84) and counselors (3.68), after the training. This is not a
surprising finding considering that 59% of the participants identified themselves as psychologists
(Table 3).
Domain Analysis
Paired sample t-tests were also conducted to evaluate whether participants showed
change in reported strength of belief in biological causation of several mental health disorders
(ADHD, anxiety, depression, substance abuse, and schizophrenia). The results indicated that
prior to the training participants were in agreement with the biological causation model of those
disorders and post-training a shift toward disagreement had occurred (Mpre = 3.02, SD = .77)
(Mpost = 3.86, SD = .88), t (75) = 9.48, p = <.001. The standardized effect size index, d was 1.09,
(see Figure 1).
A paired sample t-test was also conducted to evaluate whether the training changed the
opinions of participants in the treatment group regarding the remaining four domains
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(pharmaceutical, empirical, layperson, and guild). The results indicated that for the average
ratings on the eight items in the Empirical Domain there was significant change in the mean level
of agreement pre (Mpre = 3.29, SD = .74) to post intervention (Mpost = 4.0, SD = .76), t (75) =
9.79, p = <.001. Essentially, participant response indicated agreement that there was sufficient
empirical evidence to support a biological causation model for abnormal behaviors prior to the
training and post training there was a shift toward disagreement.
There was also significant decline noted in the attendees faith in the claims made by the
pharmaceutical industry (Mpre = 4.0, SD = .69) to post intervention (Mpost = 4.4, SD = .69), t (75)
= 6.92, p = <.001.

Increased skepticism regarding the psychiatric/medical guild’s claims of

biological causation resulted as well (Mpre = 3.1, SD = .69) (Mpost = 3.2, SD = .71), t (75) = 3.06,
p = <.01, although it was a relatively small change. There were significant changes in the
perception of the HMO industry’s influence (Mpre = 3.2, SD = .71) (Mpost = 3.0, SD = .61), t (75)
= 2.48, p = .015. However, there was no noted change in thinking among participants regarding
the influence of laypersons’ preference for biological explanations (Mpre = 3.4, SD = .69) (Mpost
= 3.4, SD = .67), t (75) = .80, p = .425 (see Table 7).
A final set of paired sample t-tests was conducted to evaluate whether participants in the
control group showed any pre-post change. Results indicated that no change occurred on any
domain (see Table 8).
A standard multiple regression was performed between the pre-post difference in strength
of belief of the biological domain as the dependent variable and the pre-post difference in
strength of the pharmaceutical domain, empirical domain, and guild domain as the independent
variables (IVs). The HMO and Layperson Domain were excluded from further evaluation given
Pearson correlations were found to be insignificant. Additional analysis included a hierarchical
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regression in which the demographic variables of sex, age, and education were controlled for
before assessing the relationship between the pre-post difference in strength of belief of the
biological domain as the dependent variable and the pre-post differences in strength of belief of
the pharmaceutical domain, empirical domain, and guild domain as the independent variables.
Table 10 displays the results for the regression analyses.

R for regression was

significantly different from zero R2 = .340, F(3, 72) = 12.377 p < .001. The combination of the
three IVs contributed significantly to prediction of strength of belief in biological causation.
Upon closer review of the regression coefficients it seems that of the three variables empirical
domain had the greatest influence (see Table 10). Age, sex, and education as predictors for
strength of belief in biological domain were not significant, R2 = .053, F(3, 72) = 1.348 p = .266.
After controlling for these demographic variables, the three domains still accounted for a
significant proportion of variability ∆ R2 = .350, F(3, 69) = 13.49 p < .001 .
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Chapter 7
Discussion
This study was designed to examine mental health professionals’ strength of belief in
biological causation of several syndromes including ADHD, unipolar depression, anxiety
disorders, and schizophrenia and whether a three-hour educational program would alter their
thinking. The training focused on critical analyses of research that is usually cited in support of
biological causation, as well as an exploration of the economic motives and methods of both
organized psychiatry and the pharmaceutical industry, as they have promoted the biological
model.
Findings are consistent with the initial hypothesis that pre-training, mental health
professionals’ reported strength of belief regarding the etiology of many mental health disorders
(e.g., ADHD, unipolar depression, anxiety disorders, and schizophrenia) would tend toward the
biologically based.

Also, this study demonstrated that attendance at a three hour training

program is able to reduce that expressed acceptance of biological causation of such disorders.
Statistically, the combination of the three IVs (empirical domain; pharmaceutical domain;
& guild domain) contributed significantly to prediction of strength of belief in biological
causation. However, it seems that, of the three variables, empirical domain had the greatest
influence. These findings suggest that mental health professionals are exposed to social
influences that may be contributing to belief systems supporting biological causation (i.e., guild
dominance; financial interests of the pharmaceutical industry; direct to consumer advertising,
etc.). However, it is challenging the validity of empirical data said to support biological
causation that contributes the most robust change in that expressed belief. This finding is
consistent with research indicating evidence enhance persuasion (Reinard, 1988).
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The workshop reviewed and critiqued studies often cited as evidence of biological
causation, including studies of brain structure, function and chemistry. It is plausible to suggest
that this part of the training resonated particularly well with the attendees give the significant pre
to post change in the empirical domain. That is especially interesting when one considers that
the change occurred in experienced professionals, individuals whom one might suppose had
become inured against substantial world-view changes. In that sense, the findings are quite
encouraging.
Exploration of the connection between the financial interests of the pharmaceutical
industry and the growth of the biological causation model had significant impact, even though
attendees already possessed some skepticism. Attendees came to the training with some
conviction that the financial interests of drug companies have brought about unverified claims of
drug effectiveness. However, post training findings indicated a strengthening of that pre-existing
skepticism. It appeared that the workshop’s attention to pharmaceutical company advertising to
both physicians and consumers had impact upon the professionals’ thinking. Methodological
issues (the wash-out phase, for example) and interpretative difficulties in studies of drug
effectiveness were also brought to the attention of participants. Following training, attendees
disagreed more strongly with the notion that drug study subjects are representative of patients for
whom the drugs are routinely prescribed. Similarly, the placebo effect of psychotropic drugs,
while generally well known, was also seen as more powerful, post-training.
By the workshop’s end, attendees were less likely to agree that each specific disorder
mentioned in the SOBS is caused by biological factors. The disorders and the amount of change
on the six-point scale in the “disagree” direction were: anxiety disorders (.77), depressive
disorders (.86), ADHD (1.22), schizophrenia (.94) and addiction (.66). Thus, the findings
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suggests that greater understanding of the research and of the related phenomena, such as the
pharmaceutical industry’s advertising practices, tends to significantly weaken the mental health
professional’s belief in biological causation. That is true generally and for a number of specific
disorders and classes of disorders.
A number of attendees informally remarked that the training “had opened their eyes” to
research issues that they had not considered and had not been taught in their graduate training.
Others pointed out that they had already felt skepticism about claims of drug companies, but that
the training helped them gain focus on the specifics. Still others commented that the guild
interests of organized psychiatry were not new to them, but that they had been unaware of the
extent to which those interests had become highly symbiotic with drug industry interests.
A number of suggestions arise from the study. Given that empirical evidence serves as
the food for thought, further research might well start there first. We know that studies can
contain significant methodological flaws that may become evident only with close scrutiny. We
also know that time constraints and access to data are barriers to such critical review of the body
of research published, particularly for busy, front-line treating professionals. At a glance, the
randomized double-blind, placebo controlled studies such as those published in the Journal of
American Medical Association (JAMA) can appear quite convincing, specifically when it comes
to data on drug efficacy. As one journal editor put it, the quality of the journal will bless the
quality of the drug (Smith, 2005). Most professionals trust the journal as a peer reviewed
reliable and valid source of information. However, some have raised a concern that medical
journals are evolving into extensions of the marketing arms of pharmaceutical companies (Smith,
2005). Editors are required to meet budgeting demands as well as provide scholarly articles for
professional view. The pharmaceutical industry has become quite skilled at asking the right
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question rather than engaging in crude efforts to “fudge” with the results. For example, a
comparison study may demonstrate that drug A works better than drugs B and C. However, with
closer inspection one might find that either 1) the dosage of B and C are not commensurate with
that of drug A; or 2) drugs B and C are already known not to be effective for the disorder under
study. Drug companies are able to produce sophisticated models and statistical designs while an
editor typically does not have the resources to ferret out such occurrences. The pharmaceutical
industry’s financial strength dominates publications in that they underwrite 75% of the studies
published in the major journals – Annals of Internal Medicine, JAMA, Lancet, and New England
Journal of Medicine (Smith, 2005). On one hand one is hard pressed to fault the pharmaceutical
industry for making money. On the other hand it is reasonable to consider that certain health
industry practices can create conflicts of interest that require regulation (Brennan; Rothman;
Blank; Blumenthal; Chimonas; Cohen; Goldman; Kassirer; Kimball; Naughton; & Smelser,
2006).
There is need for more public funding of trials, particularly of large head-to-head trials of
all treatments available for treating a given disorder. A federally regulated web site could house
the studies. Journal editors could then concentrate on critically describing them instead of
publishing authored reports as presented for submission (Smith, 2005).
We would also do well to re-orient both the professional and popular cultures as to what
is, and is not, known about the causes of abnormal behavior. Authors of textbooks, such as
textbooks that likely were read by the professionals in this study during their training, should
revise their books’ sections dealing with biological causation. They should pay special attention
to the data said to support biological causation, and they should offer in-depth, critical analyses
of those data.
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Additionally, textbook authors and college and university professors would do well to
address cultural influences, such as the pharmaceutical industry’s direct-to-consumer advertising
and advertising to physicians, as those practices influence public and professional views of
causation. Research indicates that DTC advertising of prescription drugs via television,
magazines and billboards has become one of the hottest revenue producers in the history of mass
media in the U.S. and has also given some drugs the kind of instant brand recognition previously
reserved for autos, soft drinks and detergents (Korcok, 2002). Research demonstrates that when
a consumer responds to an “ask your doctor” commercial, over-prescribing of medication occurs
even when the patient presents with minor symptoms (Kravitz et al., 2005). One suggestion that
might right the ship of consumer information is for the Federal Trade Commission (FTC) to
move more forcefully to replace marketed drug company ‘education’ with scientifically based,
useful information that will stimulate better conversations between doctors and patients.
Studies suggest that the information provided to physicians by drug company
representatives can be biased and incorrect, and that physicians often cannot distinguish true
statements from false ones as they are presented with sales pitches. Many physicians are not
aware of the extent to which commercial sources of information shape their own prescribing
practices. For example, most physicians believe gifts given by pharmaceutical representatives do
not influence their own prescribing practices, but these same physicians also believe that gifts do
influence their colleagues (Steinman, Shlipak, & McPhee, 2000; Hopper, Speece, & Musial,
1990).
Improving physicians’ awareness of the consequences of gift giving may be enhanced by
institution of polices and educational programs that address this topic. Medical school and
residency training programs should incorporate training on how to deal with pharmaceutical
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representatives. The gift giving “norm” should be challenged and eliminated.
It is possible that improved government regulation of the claims made by the drug
industry, mass media organizations, and doctors’ groups may be of help. Recently the
government has increased its scrutiny of the claims of the drug industry regarding possible lifethreatening effects of anti-depressants with children and youth. More needs to be done to
reinforce the reliability and accuracy of information disseminated to the consumer, especially
considering the impact it has on the consumers’ decisions about treatment.
The current sets of social and cultural influences seem to validate biological causation.
Therefore the need for biological treatment is presently culturally functional. Because without it
there would be a void. Competing models may be better brought into focus, for example we
know that learning theory is a plausible basis for perspectives on the etiology and maintenance of
anxiety disorders (Mineka & Zinbarg, 2006). Similarly, the etiology of depression has long been
attributed by cognitive therapists to a negative cognitive or attribution style and some
unfortunate, stressful experience (Seligman, 1975; Abramson, Metalsky, & Alloy, 1989). This
may appear to be a difficult process given the enormous financial support available to the
pharmaceutical industry and to organized medicine. However, large funding resources, such as
the National Institute of Mental Health may yet be convinced to support different etiological
perspectives of mental health syndromes as well as treatment interventions.
Limitations
One issue in interpretation of this study’s results is that conceptualization of causation as
either “biological” or “not biological” leaves open the question of contributions of both biology
and environment. The intent of this research was to test the hypothesis that mental health
professionals’ belief systems are more aligned with the biological causation of many mental
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health disorders as well as whether their beliefs were amenable to change. In an attempt to
calibrate participant response the SOBS allowed only for six options (1 through 6 with 1 =
Strongly Agree: 6 = Strongly Disagree). As a result, the middle ground posture became more
clearly defined, at least numerically speaking. However, it is difficult to gain a true sense or
source for participant agreement or disagreement by way of metric design. This study did not
explore the psychological realities surrounding the different scores on this scale; therefore the
SOBS response metric is vulnerable to subjective inferences.
A second concern arises when considering the presentation of data and inferred change as
a result of such presentation. It is difficult to extract the influence of expert power (factual
information provided by a skilled presenter) from prestige or referent power (well known
professor and likeable figure) when inferring subject response to items (French & Raven, 1959,
Aronson & Golden, 1962; Berlo, Lemest & Martin, 1969; Eagly, Wood & Chaiken, 1978;
Haughtvedt, 1997). Therefore leaving open for speculation, is it the message or the messenger
that brought about change?
A third consideration in interpretation of this study’s conclusion lies in the measuring of
change. One must be cautious not to make inferences regarding the magnitude of change on a
true psychological dimension based simply on the magnitude of observed change on the
observed metric. It is impossible to translate just how much one unit of change toward
disagreement actually converts to, especially in terms of change in actual practice. All that can
be said is that it reflects some degree of change, but how much is unknown (Blanton & Jaccard,
2006).
A fourth consideration should also be given to the how long will the observed change
last? This could be a spring board for additional research.
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Conclusion
There exists within the US culture a dynamic relationship between the pharmaceutical
industry, the medical industry, regulatory bodies, mass media organizations, non-medical mental
health practitioners and the mental health patient that is so strong that change in it will require a
major pendulum swing away from biological causation as it currently is perceived. Although it
was not this study’s mandate to modulate the debate between etiological bases of behavior and
treatment practices, it is a premise for starting such debate. This was an effort to heighten
awareness that there are social influences such as money, marketing, and guild dominance that
are impacting the mental health professionals’ belief systems. A change in the professional
attitude and understanding is possible and with sustained effort it is encouraging that certain
growth [and change] can occur in the treatment for many mental health problems.
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Appendix I
PRE SURVEY ________Last 4 Digits of SSN

STRENGTH OF BELIEF SCALE (SOBS)
Identifying Data:
Discipline

Education

Psychologist

Social Worker

Counselor

Psychiatrist

Other (describe)

High School

Associate

BA

Masters

Doctoral

BS

Presently in school/training in ________________ (program)

Sex

Female

Male

Age Group

18 – 26

27 – 35

36 – 44

45 – 53

54 – 62

63+

Primary Job
Location
Full Time
Part Time

Community Mental Health

State Hospital

Private Practice

General Hospital

For Profit Psych Hospital

University

Other (describe)
Directions: Please read each question carefully and respond by circling a number on the scale at right with one (1)
Strongly Agree to six (6) Strongly Disagree

1.

Attending pharmaceutical company sponsored workshops
is helpful for me to understand the benefits of psychotropic
medication.

2.

Anxiety is a biological disorder.

SA
SD
1---2---3---4---5---6

1---2---3---4---5---6
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SA
SD
1---2---3---4---5---6

3.

In studies of effectiveness of psychotropic drugs,
the people who take the experimental drugs are
representative of the general population.

4.

Medication is less costly than
psychotherapy
in the eyes of Health Maintenance
Organizations (HMO) and other health insurance
agencies.

1---2---3---4---5---6

5.

Doctors are experts.

1---2---3---4---5---6

6.

Most people in America think that a diagnosis
of a mental illness implies a person is weak.

1---2---3---4---5---6

7.

Family physicians acquire their practical knowledge
about psychotropic medication from the pharmaceutical
company representatives.

1---2---3---4---5---6

8.

A mental illness believed to be biologically
treated offers greater hope for recovery than
non-biologically caused mental illnesses.

1---2---3---4---5---6

9.

Health Maintenance Organizations (HMO) and other
health insurance agencies limit coverage of the number
of psychotherapy sessions much more so than the
number of office visits for medication refills.

1---2---3---4---5---6

10. Social workers are well suited to diagnose and
treat mental disorders.

1---2---3---4---5---6

11. Financial interests of pharmaceutical companies have
brought about unverified claims of causation of
mental disorders

1---2---3---4---5---6

12. Medical doctors are figures of authority.

1---2---3---4---5---6

13. Unipolar depression is a biological disorder.

1---2---3---4---5---6

14. Studies of identical twins who were separated soon after
birth and reared apart show fairly high levels of
concordance for various mental and behavioral disorders.
(Concordance means if one twin develops a disorder such
as depression or schizophrenia later in life, then the other
develops it too).

1---2---3---4---5---6

15. Studies have shown that people with psychological
problems have more or less of certain brain chemicals
called neurotransmitters.

1---2---3---4---5---6

16. Most people in America think that a diagnosis
of a mental illness implies a person has not tried
to overcome his or her problem.

1---2---3---4---5---6
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17. Pharmaceutical company television advertisements for
psychotropic medications are believable.

SA
SD
1---2---3---4---5---6

18. Health Maintenance Organizations (HMO) and
other health insurance agencies put the patient first.

1---2---3---4---5---6

19. Medical doctors should be believed.

1---2---3---4---5---6

20. Psychiatrists are well suited to diagnose and
treat mental disorders.

1---2---3---4---5---6

21. ADHD is a biological disorder.

1---2---3---4---5---6

22. The majority of mental disorders are biological illnesses
rather than the result of poorly learned coping skills.

1---2---3---4---5---6

23. Schizophrenia is a biological disorder.

1---2---3---4---5---6

24. Psychologists are well suited to diagnose and
treat mental disorders.

1---2---3---4---5---6

25. Most of my knowledge about psychotropic medication
comes from pharmaceutical company representatives.

1---2---3---4---5---6

26. Studies of identical twins who were separated soon after
birth and reared apart that show fairly high levels of
concordance for various mental and behavioral disorders
provides strong evidence for biological causation of
mental disorders.

1---2---3---4---5---6

27. Counselors are well suited to diagnose and treat
mental disorders.

1---2---3---4---5---6

28. Psychiatrists acquire a significant amount of their
practical knowledge about psychotropic medication from
the pharmaceutical company representatives.

1---2---3---4---5---6

29. Addiction is a biological disorder.

1---2---3---4---5---6

30. It is important to listen to those of authority.

1---2---3---4---5---6

31. There is evidence that biological abnormalities
such as chemical imbalances, brain lesions or genetic
abnormalities cause most mental disorders.

1---2---3---4---5---6

32. When depressed patients are given an antidepressant a
large percentage of the patients improvement is due
to the placebo effect.

1---2---3---4---5---6

33. Asking my doctor about medications advertised on
television can be helpful in finding the right medication
that will meet my needs.

1---2---3---4---5---6
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34. If in the future, scientists identify a specific gene
that pre-disposes people to become mentally ill,
this would prove that mental illness is a disease.

SA
SD
1---2---3---4---5---6

35. Studies that show people with psychological
problems who have more or less of certain brain chemicals
provides strong evidence for biological causation of
mental disorders.

1---2---3---4---5---6

36. I trust that the medication prescribed to me by my doctor
is what I need.

1---2---3---4---5---6

37. If an expert said so it must be true.

1---2---3---4---5---6

38. The majority of mental disorders are biological illnesses
rather than habit disorders .

1---2---3---4---5---6
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Appendix II
POST SURVEY ________Last 4 Digits of SSN

STRENGTH OF BELIEF SCALE (SOBS)
Identifying Data:
Discipline

Education

Psychologist

Social Worker

Counselor

Psychiatrist

Other (describe)

High School

Associate

BA

Masters

Doctoral

BS

Presently in school/training in ________________ (program)

Sex

Female

Male

Age Group

18 – 26

27 – 35

36 – 44

45 – 53

54 – 62

63+

Primary Job
Location
Full Time
Part Time

Community Mental Health

State Hospital

Private Practice

General Hospital

For Profit Psych Hospital

University

Other (describe)
Directions: Please read each question carefully and respond by circling a number on the scale at right with one (1)
Strongly Agree to six (6) Strongly Disagree

1.

In studies of effectiveness of psychotropic drugs,
the people who take the experimental drugs are
representative of the general population.

2.

Doctors are experts.

SA
SD
1---2---3---4---5---6

1---2---3---4---5---6
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SA
SD
1---2---3---4---5---6

3.

Medication is less costly than psychotherapy
in the eyes of Health Maintenance
Organizations (HMO) and other health insurance
agencies.

4.

Attending pharmaceutical company sponsored workshops
is helpful for me to understand the benefits of psychotropic
medication.

1---2---3---4---5---6

5.

Most people in America think that a diagnosis
of a mental illness implies a person is weak.

1---2---3---4---5---6

6.

Family physicians acquire their practical knowledge
about psychotropic medication from the pharmaceutical
company representatives.

1---2---3---4---5---6

7.

A mental illness believed to be biologically
treated offers greater hope for recovery than
non-biologically caused mental illnesses.

1---2---3---4---5---6

8.

Health Maintenance Organizations (HMO) and other
health insurance agencies limit coverage of the number
of psychotherapy sessions much more so than the
number of office visits for medication refills.

1---2---3---4---5---6

9.

Social workers are well suited to diagnose and
treat mental disorders.

1---2---3---4---5---6

10. Anxiety is a biological disorder.

1---2---3---4---5---6

11. Financial interests of pharmaceutical companies have
brought about unverified claims of causation of
mental disorders

1---2---3---4---5---6

12. Medical doctors should be believed.

1---2---3---4---5---6

13. Unipolar depression is a biological disorder.

1---2---3---4---5---6

14. Studies of identical twins who were separated soon after
birth and reared apart show fairly high levels of
concordance for various mental and behavioral disorders.
(Concordance means if one twin develops a disorder such
as depression or schizophrenia later in life, then the other
develops it too).

1---2---3---4---5---6

15. Studies have shown that people with psychological
problems have more or less of certain brain chemicals
called neurotransmitters.

1---2---3---4---5---6

16. Most people in America think that a diagnosis
of a mental illness implies a person has not tried

1---2---3---4---5---6
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to overcome his or her problem.
17. Pharmaceutical company television advertisements for
psychotropic medications are believable.

SA
SD
1---2---3---4---5---6

18. Health Maintenance Organizations (HMO) and
other health insurance agencies put the patient first.

1---2---3---4---5---6

19. Psychiatrists are well suited to diagnose and
treat mental disorders.

1---2---3---4---5---6

20. Medical doctors are figures of authority.

1---2---3---4---5---6

21. ADHD is a biological disorder.

1---2---3---4---5---6

22. The majority of mental disorders are biological illnesses
rather than the result of poorly learned coping skills.

1---2---3---4---5---6

23. The majority of mental disorders are biological illnesses
rather than habit disorders .

1---2---3---4---5---6

24. Schizophrenia is a biological disorder.

1---2---3---4---5---6

25. Psychologists are well suited to diagnose and
treat mental disorders.

1---2---3---4---5---6

26. Most of my knowledge about psychotropic medication
comes from pharmaceutical company representatives.

1---2---3---4---5---6

27. Studies of identical twins who were separated soon after
birth and reared apart that show fairly high levels of
concordance for various mental and behavioral disorders
provides strong evidence for biological causation of
mental disorders.

1---2---3---4---5---6

28. If an expert said so it must be true.

1---2---3---4---5---6

29. Psychiatrists acquire a significant amount of their
practical knowledge about psychotropic medication from
the pharmaceutical company representatives.

1---2---3---4---5---6

30. Addiction is a biological disorder.

1---2---3---4---5---6

31. It is important to listen to those of authority.

1---2---3---4---5---6

32. There is evidence that biological abnormalities
such as chemical imbalances, brain lesions or genetic
abnormalities cause most mental disorders.

1---2---3---4---5---6

33. When depressed patients are given an antidepressant a
large percentage of the patients improvement is due
to the placebo effect.

1---2---3---4---5---6

34. Asking my doctor about medications advertised on

1---2---3---4---5---6
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television can be helpful in finding the right medication
that will meet my needs.
35. If in the future, scientists identify a specific gene
that pre-disposes people to become mentally ill,
this would prove that mental illness is a disease.

SA
SD
1---2---3---4---5---6

36. Studies that show people with psychological
problems who have more or less of certain brain chemicals
provides strong evidence for biological causation of
mental disorders.

1---2---3---4---5---6

37. I trust that the medication prescribed to me by my doctor
is what I need.

1---2---3---4---5---6

38. Counselors are well suited to diagnose and treat
mental disorders.

1---2---3---4---5---6
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Appendix III
BIOLOGICAL DOMAIN (7 Items)
1.

The majority of mental disorders are biological illnesses, rather than habit disorders.

2.

The majority of mental disorders are biological illnesses, rather than the result of poorly learned coping
skills.

3.

Unipolar depression is a biological disorder.

4.

Addiction is a biological disorder.

5.

Schizophrenia is a biological disorder.

6.

ADHD is a biological disorder.

7.

Anxiety is a biological disorder.

LAYPERSON PREFERENCE (5 Items)
39. Most people in America think that a diagnosis of a mental illness implies a person is weak.
40. If an expert said so it must be true.
41. Most people in America think that a diagnosis of a mental illness implies a person has not tried to
overcome his or her problem.
42. Doctors are experts.
43. A mental illness believed to be biologically treated offers greater hope for recovery than non-biologically
caused mental illnesses.
EMPIRICAL DOMAIN (8 Items)
1.

Studies of identical twins who were separated soon after birth and reared apart show fairly high levels of
concordance for various mental and behavioral disorders. (Concordance means if one twin develops a
disorder such
as depression or schizophrenia later in life, then the other
develops it too).

2.

Studies of identical twins who were separated soon after birth and reared apart that show fairly high levels
of concordance for various mental and behavioral disorders provides strong evidence for biological
causation of
mental disorders.

3.

Studies that show people with psychological problems who have more or less of certain brain chemicals
provides strong evidence for biological causation of
mental disorders.

4.

Studies have shown that people with psychological problems have more or less of certain brain chemicals
called neurotransmitters.
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5.

If in the future, scientists identify a specific gene that pre-disposes people to become mentally ill, this
would prove that mental illness is a disease.

6.

In studies of effectiveness of psychotropic drugs, the people who take the experimental drugs are
representative of the general population.

7.

When depressed patients are given antidepressant a large percentage of the patients improvement is due to
the placebo effect.

8.

There is strong evidence that biological abnormalities such as chemical imbalances, brain lesions or genetic

PHARMACEUTICAL INFLUENCE (7 Items)
1.

Attending pharmaceutical company sponsored workshops is helpful for me to understand the benefits of
psychotropic medication.

2.

Pharmaceutical company television advertisements for psychotropic medications are believable.

3.

Most of my knowledge about psychotropic medication comes from pharmaceutical company
representatives.

4.

Asking my doctor about medications advertised on television can be helpful in finding the right medication
that will meet my needs.

5.

Financial interests of pharmaceutical companies have brought about unverified claims of causation of
mental disorders.

6.

Family physicians acquire a significant amount of their practical knowledge about psychotropic medication
from the pharmaceutical company representatives.

7.

Psychiatrists acquire a significant amount of their practical knowledge about psychotropic medication from
the pharmaceutical company representatives.

GUILD INFLUENCE (8 Items)
1.

Medical doctors should be believed.

2.

Psychiatrists are well suited to diagnose and treat mental disorders.

3.

Counselors are well suited to diagnose and treat mental disorders.

4.

Social workers are well suited to diagnose and treat mental disorders.

5.

Medical doctors are figures of authority.

6.

It is important to listen to those of authority.

7.

I trust that the medical advice given to me by my doctor is true.

8.

Psychologists are well suited to diagnose and treat mental disorders.

HEALTH MAINTENANCE ORGANIZATION (HMO) DOMAIN (3 Items)
1.

Health Maintenance Organizations (HMO) and other health insurance agencies put the patient first.
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2.

Health Maintenance Organizations (HMO) and other health insurance agencies limit coverage of the
number of psychotherapy sessions much more so than the
number of office visits for medication refills.

3.

Medication is less costly than psychotherapy in the eyes of Health Maintenance
Organizations (HMO) and other health insurance agencies.
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Table Caption
Table 1 Frequency of Age
Age
18-26
27-35
36-44
45-53
54-62
63+

Frequency
2
14
8
25
20
76

Percent
2.6
18.4
10.5
32.9
26.3
9.2

Table 2 Frequency of Education
Highest Grade Completed

Frequency

Percent

2
2
13
31
28

2.6
2.6
17.1
40.8
36.8

High School
Associate
Bachelor
Masters
Doctoral

Table 3 Frequency of Discipline
Discipline
Psychologist
Social Worker
Counselor
Other

Frequency
45
11
12
8

Percent
59.2
14.5
15.8
10.5

Table 4 Frequency of Employment
Frequency
7
2
28
2
11
6
20

Community Mental Health
State Hospital
Private Practice
General Hospital
For Profit Psychiatric Hospital
University
Other

Percent
9.2
2.6
36.8
2.6
14.5
7.9
26.3

Table 5 2001 to 2002 Psychotropic Sales Growth
Drug
Zyprexa
Zoloft
Paxil
Neuronton
Risperdal

Percent Sales Growth
17%
14.2%
10.7%
20.4%
12.9%

Revenue (Billions)
$2.8
$2.5
$2.3
$2.0
$1.8
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Table 6 Reliability Analysis of Each Domain
Domain
Biological Domain
Layperson Domain
Empirical Domain
Pharmaceutical Domain
Guild Domain
HMO Domain

r
.73
.76
.77
.82
.87
.57

r = coefficient alpha

Table 7 Pre and Post Training Means of Treatment Group.
Domain
Biological Domain
Layperson Domain
Empirical Domain
Pharmaceutical Domain
Guild Domain
HMO Domain
Mpre = pretest mean
Mpost = posttest mean
Mdiff = Mpre - Mpost
SDdiff = standard deviation of Mdiff
d = Cohen’s measure of effect size
*p < .01
**p < .001

Mpre
3.02
3.4
3.3
4.0
3.1
3.2

Mpost
3.86
3.5
4.0
4.4
3.2
3.1

Mdiff
-.83**
-.1
-.7**
-.44**
-.2*
.2

SDdiff
.8
.6
.7
.55
.5
.7

Mdiff
.1
.1
.1
-.1
-.03
.2

SDdiff
.5
.4
.5
.4
.4
.6

Table 8 Pre and Post Training Means of Control Group
Domain
Biological Domain
Layperson Domain
Empirical Domain
Pharmaceutical Domain
Guild Domain
HMO Domain
Mpre = pretest mean
Mpost = posttest mean
Mdiff = Mpre - Mpost
SDdiff = standard deviation of Mdiff
*p < .01
**p < .001

Mpre
3.1
2.9
2.9
3.9
3.2
3.2

Mpost
3.0
2.7
2.8
4.0
3.2
3.0
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Table 9 Individual Item Comparison of Means (Items are in Appendix I order)
SOBS Item
Item 1 Attending pharmaceutical is helpful …
Item 2 Anxiety is a biological disorder …
Item 3 In studies of effectiveness people represent..
Item 4 HMO sees meds as less costly than …
Item 5 Doctors are experts …
Item 6 Mental illness implies weak …
Item 7 General doc & drug knowledge comes ...
Item 8 Biological model offers hope …
Item 9 HMO limits psychotherapy…
Item 10 SW are well suited to dx & tx …
Item 11 Financial interest & drug co = ? claim .
Item 12 Medical doctors are figures of auth…
Item 13 Depression is a biological disorder …
Item 14 Studies of identical twins …
Item 15 Studies have shown …
Item 16 Most people in America …
Item 17 Drug co. tv ads are believable …
Item 18 HMOs put the patient first …
Item 19 Med docs should be believed
Item 20 Psychiatrist are well suited to dx & tx …
Item 21 ADHD is a biological disorder …
Item 22 The majority of MI are bio illness…
Item 23 Schizophrenia is a biological disorder...
Item 24 Psychologists are well suited to dx & tx …
Item 25 My knowledge about drugs comes from…
Item 26 High concordance rates is strong evidence..
Item 27 Counselors are well suited to dx & tx…
Item 28 Psychiatrist knowledge of drugs come …
Item 29 Addiction is a biological disorder …
Item 30 It is important to listen to authority …
Item 31 There is evidence that bio abnormalities …
Item 32 Depressed patients improve due to placebo.
Item 33 Asking my doc about drug tv ads helps …
Item 34 ID of a gene means MI is a disease…
Item 35 Studies show more or less of brain chem…
Item 36 I trust the meds prescribed is what I need…
Item 37 If an expert said so it must be true …
Item 38 Majority of MI are biological …
Mpre = pretest mean
Mpost = posttest mean
Mdiff = Mpre - Mpost
*p < .01

Mpre
2.68
3.34
4.12
2.48
3.34
2.68
4.58
3.78
1.97
4.10
4.40
2.59
2.96
2.75
3.00
2.74
3.63
5.30
3.45
2.36
2.57
3.62
1.91
1.86
4.20
2.72
3.74
4.45
3.21
3.32
3.59
3.37
3.84
3.57
3.23
3.22
4.69
3.57

Mpost
4.05
4.11
4.78
2.12
4.02
2.32
4.61
3.76
1.84
3.80
5.08
2.93
3.82
3.72
3.57
2.46
4.17
5.25
3.61
2.84
3.79
4.32
2.85
1.97
4.05
4.14
3.68
4.53
3.87
3.77
4.55
4.24
4.33
3.97
4.19
3.44
4.77
4.17

Mdiff
-1.37*
-.77*
-.66*
.36*
-.68
.36
-.03
.02
.13
.30
-.68*
-.34
-.86*
-.97*
-.57*
.28
-.54*
.05
-.16
-.48*
-1.22*
-.70*
-.94*
-.11
.15
-1.42*
.06
-.08
-.66*
-.45*
-.96*
-.87*
-.49*
-.40*
-.96*
-.22
-.08
-.60*
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Table 10 Standard Multiple Regression of Guild, Empirical & Pharmaceutical Influences on the
Strength of Belief (SOB) in Biological Causation.
Variables

SOB BDMN
DV

G-INF

E-INF

G-INF

.355

E-INF

.530

.409

.395

.271

.380

.8302

.1702

.7319

P-INF
MEANS
STANDARD
DEVIATIONS

.76367

.48437

.65137

*p < .01
**p < .001
SOB = Strength of Belief Scale
BDMN = Biological Domain
G-INF = Guild Influence
E-INF = Empirical Influence
P-INF = Pharmaceutical Influence
Numbers in upper left corner = Pearson Correlations

P-INF

B

β

.216

.137

.464**

.396

.288

.207

.4359
.54921

R2 =.340
Adjusted R2 =.313
R =.583**

